These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 12000202

  • 1. Effect of reboxetine on depression in Parkinson's disease patients.
    Lemke MR.
    J Clin Psychiatry; 2002 Apr; 63(4):300-4. PubMed ID: 12000202
    [Abstract] [Full Text] [Related]

  • 2. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L, Biancosino B, Marmai L, Righi R.
    J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
    [Abstract] [Full Text] [Related]

  • 3. Reboxetine treatment of depression in Parkinson's disease.
    Lemke MR.
    J Clin Psychiatry; 2000 Nov; 61(11):872. PubMed ID: 11105742
    [No Abstract] [Full Text] [Related]

  • 4. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.
    Burrows GD, Maguire KP, Norman TR.
    J Clin Psychiatry; 1998 Nov; 59 Suppl 14():4-7. PubMed ID: 9818623
    [Abstract] [Full Text] [Related]

  • 5. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M.
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [Abstract] [Full Text] [Related]

  • 6. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J.
    J Clin Psychiatry; 1998 Jan; 59 Suppl 14():8-10. PubMed ID: 9818624
    [Abstract] [Full Text] [Related]

  • 7. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC, Portera L, Leon AC.
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [Abstract] [Full Text] [Related]

  • 8. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M.
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
    [Abstract] [Full Text] [Related]

  • 9. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R.
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [Abstract] [Full Text] [Related]

  • 10. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.
    Carvalhal AS, de Abreu PB, Spode A, Correa J, Kapczinski F.
    J Clin Psychiatry; 2003 Apr; 64(4):421-4. PubMed ID: 12716244
    [Abstract] [Full Text] [Related]

  • 11. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
    Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Lewis G.
    Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
    [Abstract] [Full Text] [Related]

  • 12. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
    Hajós M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH.
    CNS Drug Rev; 2004 Feb; 10(1):23-44. PubMed ID: 14978512
    [Abstract] [Full Text] [Related]

  • 13. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
    Scates AC, Doraiswamy PM.
    Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E, Demir EY, Cosar B.
    Adv Ther; 2006 Nov; 23(6):974-87. PubMed ID: 17276965
    [Abstract] [Full Text] [Related]

  • 15. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A, Bosc M, Polin V.
    J Psychopharmacol; 1997 Nov; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
    Berzewski H, Van Moffaert M, Gagiano CA.
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
    [Abstract] [Full Text] [Related]

  • 17. The antidepressant efficacy of reboxetine in patients with severe depression.
    Montgomery S, Ferguson JM, Schwartz GE.
    J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
    [Abstract] [Full Text] [Related]

  • 18. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L, Baillès E, Valldeoriola F, Tolosa E, Martí MJ, de Pablo J.
    Gen Hosp Psychiatry; 2006 Feb; 28(1):59-64. PubMed ID: 16377367
    [Abstract] [Full Text] [Related]

  • 19. Predicting response: noradrenaline reuptake inhibition.
    Montgomery SA.
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
    [Abstract] [Full Text] [Related]

  • 20. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M.
    Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.